Cartesian Growth Corporation III
NASDAQ:CGCTShell Companies
-$1.91 today
- Market cap
- $328.44M
- Beta
- 0.51
- P/E (TTM)
- 66.9
- EPS (TTM)
- $0.23
Volume 0.34M
Average 0.21M
CGCT Total Liabilities
Everything the company owes to creditors and other parties.
Cartesian Growth Corporation IIINASDAQ: CGCT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 1852.6% from a year ago
Total liabilities stood at $14.53M at the end of Q1 FY2026, up 1852.6% from a year earlier and up 4.0% from the prior quarter.
Context
- Total liabilities amounted to 5.1% of total assets at the end of Q1 FY2026, down 100.3 pp from a year earlier.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +1852.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 13.97M USD
- Year-over-year change
- +4812.1%
- 1-year CAGR
- +4812.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.97M | +4812.1% |
| FY2024 | 2024-12-31 | 284.5K | — |
Total Liabilities vs competitors
How CGCT compares with its peers on the latest reported figures
- CGCT's Mar 2026 total liabilities of $14.53M is the 3rd highest of the 9 companies compared; the peer median is $10.95M.
- Its year-over-year change of +1852.6% is the 4th highest of 9, against a peer median of +37.0%.
- Total liabilities amounts to 5.1% of total assets for CGCT, versus a peer median of 4.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
MBAVM3-Brigade Acquisition V Corp. Class A Ordinary shares | Mar 2026 | $21.4M | +50.0% | — | 6.9% |
AACBArtius II Acquisition Inc. Class A Ordinary Shares | Mar 2026 | $15.77M | +24.0% | — | 6.8% |
| Mar 2026 | $14.53M | +1852.6% | — | 5.1% | |
| Mar 2026 | $13.99M | +4450.2% | — | 5.3% | |
| Mar 2026 | $11.06M | +9.9% | — | 4.5% | |
POLEAndretti Acquisition Corp. II | Mar 2026 | $10.84M | +9.7% | — | 4.4% |
| Mar 2026 | $9.76M | +2161.9% | — | 3.9% | |
LEGTLegato Merger Corp. III | Feb 2026 | $7.04M | +0.0% | — | 3.2% |
| Mar 2026 | $7M | +2942.7% | — | 3.9% | |
| Peer median (excluding CGCT) | $10.95M | +37.0% | — | 4.4% | |
Competitors are the stored peer set for CGCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 0 | 624.16K |
| Short-term Investments | 0 | 0 |
| Net Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 0 | 0 |
| Total Current Assets | 3.2K | 740.14K |
| Property, Plant & Equipment (Net) | 0 | 0 |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 0 | 283.38M |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 263.68K | 37.44K |
| Total Non-current Assets | 263.68K | 283.41M |
| Total Assets | 266.88K | 284.15M |
| Account Payables | 0 | 0 |
| Short-term Debt | 41.63K | 0 |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 0 | 0 |
| Other Current Liabilities | 0 | 834.87K |
| Total Current Liabilities | 284.5K | 834.87K |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 0 | 13.14M |
| Total Non-current Liabilities | 0 | 13.14M |
| Total Liabilities | 284.5K | 13.97M |
| Common Stock | 575 | 283.38M |
| Retained Earnings | (42.62K) | (13.2M) |
| Accumulated OCI | 0 | 0 |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | (17.62K) | 270.18M |
| Total Debt | 41.63K | 0 |
| Net Debt | 41.63K | (624.16K) |
Cartesian Growth Corporation III
NASDAQ:CGCT
Intrinsic Alpha fair value
Locked
Current Price
$16.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.